The associations among eNOS G894T gene polymorphism, erectile dysfunction, and benign prostate hyperplasia-related lower urinary tract symptoms

Journal of Sexual Medicine

Volumn 6, Issue 11, 2009, Pages 3158-3165

  Lee, Yung Chin ^a,b,c   Wu, Wen Jeng ^a,b   Liu, Chia Chu ^b,c   Wang, Chii Jye ^a,b   Li, Wei Ming ^a   Huang, Chun Hsiung ^a,b   Yeh, Hsin Chih ^a   Ke, Hung Lung ^b,c   Huang, Shu Pin ^a,b,d  

^a KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^d KAOHSIUNG MUNICIPAL HSIAO KANG HOSPITAL   (Taiwan)

Author keywords

Erectile dysfunction; Gene polymorphism; Lower urinary tract symptoms

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE;

ADULT; AGED; AGING; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; ERECTILE DYSFUNCTION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; HETEROZYGOTE; HUMAN; INTERNATIONAL PROSTATE SYMPTOM SCORE; LOWER URINARY TRACT SYMPTOM; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK FACTOR;

EID: 70649089524     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2009.01353.x     Document Type: Article

References (40)

1. Garraway WM, Collins GN, Lee RJ. High prevalence of benign prostatic hypertrophy in the community. Lancet 1991, 338:469-71.
2. Rosen R, Altwein J, Boyle P, Kirby RS, Lukacs B, Meuleman E, O'Leary MP, Puppo P, Robertson C, Giuliano F. Lower urinary tract symptoms and male sexual dysfunction: The multinational survey of the aging male (msam-7). Eur Urol 2003, 44:637-49.
3. Khoo EM, Tan HM, Low WY. Erectile dysfunction and comorbidities in aging men: An urban cross-sectional study in Malaysia. J Sex Med 2008, 5:2925-34.
4. Lombardi G, Mondaini N, Giubilei G, Macchiarella A, Lecconi F, Del Popolo G. Sacral neuromodulation for lower urinary tract dysfunction and impact on erectile function. J Sex Med 2008, 5:2135-40.
5. Rhoden EL, Riedner CE, Fornari A, Fuchs SC, Ribeiro EP. Evaluation of the association between lower urinary tract symptoms and erectile dysfunction, considering its multiple risk factors. J Sex Med 2008, 5:2662-8.
6. Taylor JM, Desouza R, Wang R. Common approach to managing lower urinary tract symptoms and erectile dysfunction. Asian J Androl 2008, 10:45-53.
7. Jeremy JY, Angelini GD, Khan M, Mikhailidis DP, Morgan RJ, Thompson CS, Bruckdorfer KR, Naseem KM. Platelets, oxidant stress and erectile dysfunction: An hypothesis. Cardiovasc Res 2000, 46:50-4.
8. Maas R, Schwedhelm E, Albsmeier J, Boger RH. The pathophysiology of erectile dysfunction related to endothelial dysfunction and mediators of vascular function. Vasc Med 2002, 7:213-25.
9. Burnett AL, Lowenstein CJ, Bredt DS, Chang TS, Snyder SH. Nitric oxide: A physiologic mediator of penile erection. Science 1992, 257:401-3.
10. Andersson KE. Pharmacology of penile erection. Pharmacol Rev 2001, 53:417-50.
11. Hedlund P. Nitric oxide/cgmp-mediated effects in the outflow region of the lower urinary tract-Is there a basis for pharmacological targeting of cgmp?. World J Urol 2005, 23:362-7.
12. Andersson KE. Luts treatment: Future treatment options. Neurourol Urodyn 2007, 26:934-47.
13. Sairam K, Kulinskaya E, McNicholas TA, Boustead GB, Hanbury DC. Sildenafil influences lower urinary tract symptoms. BJU Int 2002, 90:836-9.
14. Mulhall JP, Guhring P, Parker M, Hopps C. Assessment of the impact of sildenafil citrate on lower urinary tract symptoms in men with erectile dysfunction. J Sex Med 2006, 3:662-7.
15. McVary K. Lower urinary tract symptoms and sexual dysfunction: Epidemiology and pathophysiology. BJU Int 2006, 97(2):23-8. suppl, discussion 44-5
16. Kedia G, Uckert S, Scheller F, Chigogidze T, Managadze L, Jonas U, Truss MC. In vitro functional responses of isolated normal human prostatic tissue to compounds interacting with the cyclic guanosine monophosphate pathway. Urology 2006, 67:1292-7.
17. Bivalacqua TJ, Usta MF, Champion HC, Kadowitz PJ, Hellstrom WJ. Endothelial dysfunction in erectile dysfunction: Role of the endothelium in erectile physiology and disease. J Androl 2003, 24:S17-37.
18. Eisenhardt A, Siffert W. Genetic risk factors for erectile dysfunction and genetic determinants of drug response-On the way to improve drug safety?. Herz 2003, 28:304-13.
19. Rosas-Vargas H, Coral-Vazquez RM, Tapia R, Borja JL, Salas RA, Salamanca F. Glu298asp endothelial nitric oxide synthase polymorphism is a risk factor for erectile dysfunction in the Mexican mestizo population. J Androl 2004, 25:728-32.
20. Lee YC, Huang CH, Wang CJ, Liu CC, Wu WJ, Chang LL, Lin HH. The associations among enos g894t gene polymorphism, erectile dysfunction and related risk factors. BJU Int 2007, 100:1116-20.
21. Lue TF. Erectile dysfunction. N Engl J Med 2000, 342:1802-13.
22. Terai A, Ichioka K, Matsui Y, Yoshimura K. Association of lower urinary tract symptoms with erectile dysfunction in Japanese men. Urology 2004, 64:132-6.
23. Rosen RC, Cappelleri JC, Smith MD, Lipsky J, Pena BM. Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res 1999, 11:319-26.
24. Ponholzer A, Temml C, Rauchenwald M, Madersbacher S. Vascular risk factors and erectile dysfunction in a cohort of healthy men. Int J Impot Res 2006, 18:489-93.
25. Bechara A, Romano S, Casabé A, Haime S, Dedola P, Hernández C, Rey H. Comparative efficacy assessment of tamsulosin vs. tamsulosin plus tadalafil in the treatment of LUTS/BPH. Pilot study. J Sex Med 2008, 5:2170-8.
26. Irwin DE, Milsom I, Reilly K, Hunskaar S, Kopp Z, Herschorn S, Coyne KS, Kelleher CJ, Artibani W, Abrams P. Overactive bladder is associated with erectile dysfunction and reduced sexual quality of life in men. J Sex Med 2008, 5:2904-10.
27. Antunes AA, Srougi M, Dall'oglio MF, Vicentini F, Paranhos M, Freire GC. The role of BPH, lower urinary tract symptoms, and PSA levels on erectile function of Brazilian men who undergo prostate cancer screening. J Sex Med 2008, 5:1702-7.
28. Kedia GT, Uckert S, Jonas U, Kuczyk MA, Burchardt M. The nitric oxide pathway in the human prostate: Clinical implications in men with lower urinary tract symptoms. World J Urol 2008, 26:603-9.
29. Chitale S, Collins R, Hull S, Smith E, Irving S. Is the current practice providing an integrated approach to the management of LUTS and ED in primary care? An audit and literature review. J Sex Med 2007, 4:1713-25.
30. Carrier S, Nagaraju P, Morgan DM, Baba K, Nunes L, Lue TF. Age decreases nitric oxide synthase-containing nerve fibers in the rat penis. J Urol 1997, 157:1088-92.
31. Rehman J, Chenven E, Brink P, Peterson B, Walcott B, Wen YP, Melman A, Christ G. Diminished neurogenic but not pharmacological erections in the 2- to 3-month experimentally diabetic f-344 rat. Am J Physiol 1997, 272:H1960-71.
32. Lin CS, Liu X, Chow S, Lue TF. Cyclic amp and cyclic gmp activate protein kinase g in cavernosal smooth muscle cells: Old age is a negative factor. BJU Int 2002, 89:576-82.
33. Musicki B, Kramer MF, Becker RE, Burnett AL. Age-related changes in phosphorylation of endothelial nitric oxide synthase in the rat penis. J Sex Med 2005, 2:347-55. discussion 355-47
34. Saenz de Tejada I, Goldstein I, Azadzoi K, Krane RJ, Cohen RA. Impaired neurogenic and endothelium-mediated relaxation of penile smooth muscle from diabetic men with impotence. N Engl J Med 1989, 320:1025-30.
35. Cellek S, Foxwell NA, Moncada S. Two phases of nitrergic neuropathy in streptozotocin-induced diabetic rats. Diabetes 2003, 52:2353-62.
36. Pieper GM, Dondlinger LA. Plasma and vascular tissue arginine are decreased in diabetes: Acute arginine supplementation restores endothelium-dependent relaxation by augmenting cgmp production. J Pharmacol Exp Ther 1997, 283:684-91.
37. Takeda M, Tang R, Shapiro E, Burnett AL, Lepor H. Effects of nitric oxide on human and canine prostates. Urology 1995, 45:440-6.
38. Ponholzer A, Madersbacher S. Lower urinary tract symptoms and erectile dysfunction; links for diagnosis, management and treatment. Int J Impot Res 2007, 19:544-50.
39. Veldman BA, Spiering W, Doevendans PA, Vervoort G, Kroon AA, de Leeuw PW, Smits P. The glu298asp polymorphism of the nos 3 gene as a determinant of the baseline production of nitric oxide. J Hypertens 2002, 20:2023-7.
40. Wang XL, Sim AS, Wang MX, Murrell GA, Trudinger B, Wang J. Genotype dependent and cigarette specific effects on endothelial nitric oxide synthase gene expression and enzyme activity. FEBS Lett 2000, 471:45-50.